Table 1. TGF-β pathway inhibitors in development in hepatocellular and pancreatic carcinomas.
| Name | Targets | Trial identifier | Current Status |
|---|---|---|---|
| TGF-β ligand inhibitors | |||
| Lerdelimumab Genzyme® | TGF-β2 | Development stopped. | |
| Metelimumab Genzyme® | TGF-β1 | Development stopped. | |
| Fresolimumab Genzyme®/Aventis® | TGF-β1, -β2, -β3 | Not currently tested in PDAC or HCC. In progress in other cancer types. | |
| LY2382770 Eli Lilly® | TGF-β1 | Not currently tested in PDAC or HCC. In progress outside oncology. | |
| Trabedersen Antisens Pharma® | TGF-β2 | NCT00844064 | Phase I/II completed. Phase II in progress. Results in a small PDAC cohort. |
| Lucanix NovaRx Corporation® | TGF-β2 | Not currently tested in PDAC or HCC. In progress in other cancer types. | |
| Disitertide Digna Biotech® | TGF-β1 | Not currently tested in PDAC or HCC. In progress outside oncology. | |
| TGF-β receptor inhibitors | |||
| LY2157299 Eli Lilly® | TGF-βRI | NCT01246986 (HCC) | Phase I completed. Phase II in progress in both NCT01373164 (PDAC) PDAC and HCC. Early phase II results in HCC. |
| LY3022859 Eli Lilly® | TGF-βRII | Phase I in progress. | |